HK1060516A1 - Carbamate compounds for use in preventing or treating neurodegenerative disorders - Google Patents

Carbamate compounds for use in preventing or treating neurodegenerative disorders

Info

Publication number
HK1060516A1
HK1060516A1 HK04103497A HK04103497A HK1060516A1 HK 1060516 A1 HK1060516 A1 HK 1060516A1 HK 04103497 A HK04103497 A HK 04103497A HK 04103497 A HK04103497 A HK 04103497A HK 1060516 A1 HK1060516 A1 HK 1060516A1
Authority
HK
Hong Kong
Prior art keywords
preventing
neurodegenerative disorders
treating neurodegenerative
carbamate compounds
carbamate
Prior art date
Application number
HK04103497A
Other languages
English (en)
Inventor
Carlos R Plata-Salaman
Boyu Zhao
Roy E Twyman
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Publication of HK1060516A1 publication Critical patent/HK1060516A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/325Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
HK04103497A 2001-02-27 2004-05-17 Carbamate compounds for use in preventing or treating neurodegenerative disorders HK1060516A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27168201P 2001-02-27 2001-02-27
PCT/US2002/005541 WO2002067925A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders
US10/081,764 US20020165273A1 (en) 2001-02-27 2002-02-21 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Publications (1)

Publication Number Publication Date
HK1060516A1 true HK1060516A1 (en) 2004-08-13

Family

ID=26765943

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04103497A HK1060516A1 (en) 2001-02-27 2004-05-17 Carbamate compounds for use in preventing or treating neurodegenerative disorders
HK04108387A HK1065486A1 (en) 2001-02-27 2004-10-26 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK04108387A HK1065486A1 (en) 2001-02-27 2004-10-26 Carbamate compounds for use in preventing or treating neurodegenerative disorders

Country Status (27)

Country Link
US (3) US20020165273A1 (ru)
EP (1) EP1383489B1 (ru)
JP (1) JP4276840B2 (ru)
KR (1) KR100910928B1 (ru)
CN (1) CN1235579C (ru)
AR (1) AR035756A1 (ru)
AT (1) ATE361745T1 (ru)
BR (1) BR0207645A (ru)
CA (1) CA2439295C (ru)
CY (1) CY1106753T1 (ru)
CZ (1) CZ301203B6 (ru)
DE (1) DE60220043T2 (ru)
DK (1) DK1383489T3 (ru)
ES (1) ES2284845T3 (ru)
HK (2) HK1060516A1 (ru)
HU (1) HUP0303264A3 (ru)
IL (2) IL157591A0 (ru)
MX (1) MXPA03007718A (ru)
MY (1) MY138156A (ru)
NO (1) NO20033798L (ru)
NZ (1) NZ527990A (ru)
PL (1) PL364680A1 (ru)
PT (1) PT1383489E (ru)
RS (1) RS51055B (ru)
RU (1) RU2300373C2 (ru)
TW (1) TWI312679B (ru)
WO (1) WO2002067925A1 (ru)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2583087C (en) * 2003-09-19 2012-07-10 Galileo Pharmaceuticals, Inc. Chroman derivatives
MX2007003278A (es) * 2004-09-16 2007-10-08 Johnson & Johnson Uso de 2-fenil-1,2-etanodiol-(id) carbamatos para tratar epileptogenesis y epilepsia.
AU2005295787A1 (en) * 2004-10-15 2006-04-27 Janssen Pharmaceutica, N.V. Carbamate compounds for use in treating neurodegenerative disorders
US20070021500A1 (en) * 2005-07-12 2007-01-25 Twyman Roy E Methods for neuroprotection
AU2005335241B9 (en) * 2005-07-26 2012-12-20 Sk Biopharmaceuticals Co., Ltd. Methods for treating substance-related disorders
KR20090076958A (ko) * 2006-10-06 2009-07-13 얀센 파마슈티카 엔.브이. 신규 (s)-(+)-2-(2-클로로페닐)-2-하이드록시-에틸 카바메이트 결정
BRPI0718324A2 (pt) * 2006-10-30 2013-11-26 Sk Holdings Métodos para o tratamento de depressão.
EP2089011A1 (en) * 2006-10-31 2009-08-19 Janssen Pharmaceutica N.V. Treatment of pervasive developmental disorders
US9018253B2 (en) 2010-07-02 2015-04-28 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate compound and muscle relaxant containing the same
KR101532823B1 (ko) * 2010-07-02 2015-07-03 (주)바이오팜솔루션즈 페닐 카바메이트 화합물 및 이를 포함하는 근육 이완제
US8609849B1 (en) 2010-11-30 2013-12-17 Fox Chase Chemical Diversity Center, Inc. Hydroxylated sulfamides exhibiting neuroprotective action and their method of use
WO2013036678A1 (en) * 2011-09-07 2013-03-14 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
KR101880584B1 (ko) * 2011-12-27 2018-07-20 (주)바이오팜솔루션즈 페닐 카바메이트 화합물의 간질의 예방 또는 치료 용도
CN105228604A (zh) 2013-03-12 2016-01-06 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
JP6200527B2 (ja) * 2013-03-12 2017-09-20 バイオ−ファーム ソリューションズ カンパニー リミテッド 神経保護用フェニルカルバメート化合物及びこれを含む組成物
CN109071424B (zh) * 2016-02-29 2022-01-14 生物药品解决方案有限公司 氨基磺酸酯衍生物化合物、其制备方法及用途
KR102635936B1 (ko) 2016-12-14 2024-02-13 에스케이바이오팜 주식회사 탈수초성 질환의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도
CN113015524A (zh) * 2018-09-21 2021-06-22 爱思开生物制药株式会社 氨基甲酸酯化合物和包含其的制剂在预防、缓解或治疗急性应激障碍或创伤后应激障碍中的用途
CA3191072A1 (en) 2020-08-31 2022-03-03 Bio-Pharm Solutions Co., Ltd. Phenyl alkyl carbamate compounds for use in preventing or treating neurodegenerative disease
US11896593B2 (en) 2020-09-10 2024-02-13 Bio-Pharm Solutions Co., Ltd. Sulfamate derivative compounds for use in treating or alleviating a psychiatric disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3313692A (en) * 1958-04-21 1967-04-11 Armour Pharma Method of inducing calming and muscle relaxation with carbamates
US3278380A (en) * 1962-02-06 1966-10-11 Armour Pharma Methods of calming employing diphenyl hydroxy carbamate compounds
US3265728A (en) * 1962-07-18 1966-08-09 Armour Pharma Substituted phenethyl carbamates
US5474990A (en) * 1989-10-20 1995-12-12 Olney; John W. Barbiturates as safening agents in conjunction with NMDA antagonists
US5492930A (en) * 1994-04-25 1996-02-20 Schering Corporation Method and formulation for treating CNS disorders
US5698588A (en) * 1996-01-16 1997-12-16 Yukong Limited Halogen substituted carbamate compounds from 2-phenyl-1,2-ethanediol
US5728728A (en) * 1996-04-10 1998-03-17 Kozachuk; Walter E. Methods of providing neuroprotection
US6232434B1 (en) * 1996-08-02 2001-05-15 Duke University Medical Center Polymers for delivering nitric oxide in vivo
ES2291454T3 (es) * 2001-02-27 2008-03-01 Ortho-Mcneil Pharmaceutical, Inc. Utilizacion de carbamatos para prevenir o tratar trastornos del movimiento.
EP1408953B1 (en) * 2001-02-27 2006-04-26 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating bipolar disorder
WO2002067927A1 (en) * 2001-02-27 2002-09-06 Ortho-Mcneil Pharmaceutical, Inc. Carbamate compounds for use in preventing or treating psychotic disorders

Also Published As

Publication number Publication date
RU2003128982A (ru) 2005-03-10
KR100910928B1 (ko) 2009-08-06
CN1235579C (zh) 2006-01-11
MY138156A (en) 2009-04-30
HK1065486A1 (en) 2005-02-25
CZ301203B6 (cs) 2009-12-09
KR20030076714A (ko) 2003-09-26
RS51055B (sr) 2010-10-31
PT1383489E (pt) 2007-06-21
HUP0303264A2 (hu) 2004-01-28
ATE361745T1 (de) 2007-06-15
MXPA03007718A (es) 2004-11-12
RU2300373C2 (ru) 2007-06-10
DK1383489T3 (da) 2007-08-06
DE60220043T2 (de) 2008-01-10
CZ20032313A3 (cs) 2004-08-18
US20090005442A1 (en) 2009-01-01
JP2004523555A (ja) 2004-08-05
RS67403A (en) 2006-12-15
NO20033798D0 (no) 2003-08-26
IL157591A0 (en) 2004-03-28
CA2439295C (en) 2010-05-25
CY1106753T1 (el) 2012-05-23
IL157591A (en) 2009-12-24
ES2284845T3 (es) 2007-11-16
EP1383489B1 (en) 2007-05-09
JP4276840B2 (ja) 2009-06-10
AR035756A1 (es) 2004-07-07
NZ527990A (en) 2006-01-27
US20020165273A1 (en) 2002-11-07
TWI312679B (en) 2009-08-01
DE60220043D1 (de) 2007-06-21
EP1383489A1 (en) 2004-01-28
HUP0303264A3 (en) 2012-07-30
WO2002067925A1 (en) 2002-09-06
US20040171679A1 (en) 2004-09-02
BR0207645A (pt) 2004-12-28
CN1503667A (zh) 2004-06-09
CA2439295A1 (en) 2002-09-06
PL364680A1 (en) 2004-12-13
NO20033798L (no) 2003-09-26

Similar Documents

Publication Publication Date Title
HK1060516A1 (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders
HUP0501116A3 (en) Oxynthomodulin for preventing or treating excess weight
ZA200503967B (en) Agent for preventing or treating neuropathy
IL157592A0 (en) Carbamate compounds for use in preventing or treating movement disorders
EP1603548A4 (en) COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
EP1356278A4 (en) METHODS AND COMPOSITIONS FOR IDENTIFYING AND TREATING NEURODEGENERATIVE DISORDERS
HUS1300035I1 (hu) Dihidroimidazolonok alkalmazása epilepszia kezelésére kutyákban
PL368556A1 (en) Methods for treating or preventing skin disorders using cd2-binding agents
EP1658072A4 (en) Compounds for the Treatment of Neurodegenerative Diseases
HUP0303261A3 (en) Carbamate compounds for use in preventing or treating bipolar disorder
IL157145A0 (en) Use of dc23 antagonists for the treatment of neoplastic disorders
ZA200307475B (en) Carbamate compounds for use in the treatment of pain.
HUP0303243A3 (en) Carbamate compounds for use in preventing and treating bipolar disorder
HUP0401965A2 (en) Filtering system for the protection against biological agents
IL182432A0 (en) Carbamate compounds for use in treating neurodegenerative disorders
IL157588A0 (en) Carbamate compounds for use in preventing or treating psychotic disorders
EP1419236A4 (en) METHODS OF TREATING OR PREVENTING SCLEROSIS BY USE OF CD2-BINDING AGENTS
ZA200307473B (en) Carbamate compounds for use in preventing or treating neurodegenerative disorders.
ZA200703883B (en) Carbamate compounds for use in treating neurodegenerative disorders
PL1867644T3 (pl) Związki heteroarylo-tetrahydropiperydylowe przydatne w leczeniu lub zapobieganiu bólu
AU2003278935A8 (en) Method and composition for treating neurodegenerative disorders
ZA200307477B (en) Carbamate compounds for use in preventing or treating movement disorders.
ZA200604723B (en) Agents for preventing and/or treating higher brain dysfunctions
TWI318876B (en) Carbamate compounds for use in preventing or treating bipolar disorder

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120221